Cytonus Therapeutics is developing a proprietary Cargocyte™ Drug Delivery Platform—engineered, synthetic cell-like delivery vehicles designed to carry multiple therapeutic payloads into hard-to-reach tissues. The company has built a pipeline of proprietary immunotherapeutic products targeting cancers, infectious diseases, inflammatory diseases, and cognitive disorders. Cargocytes are described as programmable, off-the-shelf delivery drones that can selectively, potently, and controllably deliver well-validated therapies. Cytonus will use the funds from its recent financing to continue development of this portfolio and advance payload delivery to metastatic tumors and the central nervous system. The company is led by CEO Remo Moomiaie-Qajar, MD, with Chief Scientific Innovator Richard Klemke, PhD, and executive chairman Christopher Thorne, JD-MBA. In conjunction with the financing Cytonus expanded its board and scientific advisors, including additions of Jaeyeol (Jae) An, PhD, and John C. Bell, PhD.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2023